Shares of Puma Biotechnology Inc. rallied in the extended session Thursday after the biotech company said it submitted promising follow-up data in its Food and Drug Administration marketing application for a breast cancer treatment. Puma shares jumped 17% to $40.50 after hours. In an early analysis of five years of results, the company said its breast cancer treatment neratinib reduced recurrence of the disease or death by 26% in patients given the treatment versus those given a placebo.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News